ArticleBMC health services research2026
Financial impact of participating in oncology clinical trials in a tertiary hospital in Spain.
Article in BMC health services research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to evaluate the financial impact, including medication-related costs and other costs, of conducting randomized controlled trials (RCTs) in the oncology department of a tertiary hospital.
methodsThis retrospective study included all clinical trials conducted in the oncology department from January 2018 to December 2023, regardless of the phase of clinical research or type of sponsor. The total avoided cost was calculated as the drug cost avoided minus other direct medical cost for activities performed in the hospital using data from the official publication of the autonomous community health authority.
resultsDuring the observation period, 197 clinical trials actively recruited 1,198 patients, 757 of whom completed their participation within the established timeframe and were dispensed trial medications. Drug cost avoidance totaled €25,899,148, with a median (interquartile range [IQR]) by trial of €61,034 (€5,280, €235,588). Both industry-sponsored and noncommercially sponsored studies were associated with drug cost avoidance with an absolute (relative) contribution to the total cost avoidance of €23,134,649 (89.3%) and €2,764,499 (10.7%), respectively. Other direct medical cost for activities performed in the hospital €3,274,099.80. The total cost avoidance was €22,625,048. There were large variations in cost avoidance depending on the type of tumor.
conclusionsAlthough there are large variations across types of tumors, overall, clinical trials performed at the medical oncology department of a tertiary university hospital are associated with high cost avoidance and could contribute to reducing hospital expenditures for the management of cancer.
trial registrationNot applicable.
Indexed as
Identifiers
42471672What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.